Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -167.25% is 184% below its 2-year average of -58.96%, near the low end of its 2-year range (-167.25%–11.17%).
As of the fiscal period ended Wednesday, December 31, 2025. 77.88% below its 12-month average of -94.03%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-167.25%
RETURN ON EQUITY (ROE) AVG TTM
-94.03%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.88%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-298.12%
vs the sector median at left
SL Science Holding Ltd
Market Cap
$869.18M
Return on Equity (ROE)
-167.25%
TTM Avg
-94.03%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$879.93M
Return on Equity (ROE)
N/A
TTM Avg
30.44%
3Y Avg
30.44%
5Y Avg
30.44%
Market Cap
$879.54M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$859.63M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$857.60M
Return on Equity (ROE)
-8.03%
TTM Avg
-14.58%
3Y Avg
-29.27%
5Y Avg
-30.82%
Market Cap
$885.05M
Return on Equity (ROE)
59.16%
TTM Avg
-57.78%
3Y Avg
-58.75%
5Y Avg
-57.09%
Market Cap
$848.81M
Return on Equity (ROE)
N/A
TTM Avg
-5137.85%
3Y Avg
-2593.82%
5Y Avg
-1731.57%
Market Cap
$846.93M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
Market Cap
$846.20M
Return on Equity (ROE)
-24.12%
TTM Avg
40.34%
3Y Avg
40.34%
5Y Avg
40.34%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SL Science Holding Ltd (SLBT) | $869.18M | -167.25% | -94.03% | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $879.93M | N/A | 30.44% | 30.44% | 30.44% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $879.54M | -24.02% | -108.12% | -89.93% | -68.76% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $859.63M | 75.67% | 312.76% | 285.83% | 166.15% |
| SI-BONE, Inc. (SIBN)vs › | $857.60M | -8.03% | -14.58% | -29.27% | -30.82% |
| Arbutus Biopharma Corp (ABUS)vs › | $885.05M | 59.16% | -57.78% | -58.75% | -57.09% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $848.81M | N/A | -5137.85% | -2593.82% | -1731.57% |
| QuidelOrtho Corporation (QDEL)vs › | $846.93M | -59.07% | -63.84% | -29.19% | -3.25% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $846.20M | -24.12% | 40.34% | 40.34% | 40.34% |
| Bioventus Inc. (BVS)vs › | $894.74M | 23.86% | -5.16% | -37.28% | -22.23% |
ROE
-167.3%
ROA
-135.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -167.25% |
| 2024-12-31 | -20.80% |
| 2023-12-31 | 11.17% |
